A Monocyte-centered Framework for Predicting Immunochemotherapy Efficacy in LUSC Patients

ABSTRACT: Lung cancer is the leading cause of cancer-related mortality worldwide, with lung squamous cell carcinoma (LUSC) comprising 20-30% of cases. Immunochemotherapy (IC) is the standard first-line treatment for advanced LUSC, yet reliable predictors of therapeutic response remain unavailable. Using single-cell multi-omics profiling of paired pre- and post-treatment tumor and blood samples, we observed that patients responding to IC exhibited significantly higher baseline levels of peripheral blood monocytes, tumor-infiltrating classical monocytes, and APOBEC3A+ monocytes across both compartments compared with non-responders. These associations were independently validated in additional cohorts using routine complete blood count testing and multiplex immunofluorescence analysis of native tumor t

SUBMITTER: Jiangnan Zhao 

PROVIDER: S-SCDT-10_1038-S44321-026-00410-Y | biostudies-other |

REPOSITORIES: biostudies-other